Skip to main content
254 results

With the new maintenance and reliever therapy (MART) license for children, this simple guide provides information and guidance on introducing children of 5-11 years of age safely and effectively to a MART regimen. It covers:

This document offers practical guidance on delivering evidence-based asthma care, particularly when it takes place in unplanned care settings.It focuses on the management of asthma in adults and young people aged 12 and over. 

The BTS/NICE/SIGN asthma guidelines now recommend moving away from blue (reliever) and brown (preventer) inhalers. Many people with asthma still rely on their blue inhaler despite the fact they:

Anti-inflammatory reliever (AIR) is a single inhaler treatment for asthma which can be used by people with asthma and who experience asthma symptoms twice a week or less. It removes the need to have separate preventer (brown) and reliever (blue) inhalers. 

This document is a distillation of the new guidance to provide distinct advice on the changes on the diagnosis and management to asthma. It is not intended to be a comprehensive guide of the new guideline, neither does it cover all non-pharmacological treatments or on-going monitoring.

Maintenance and reliever therapy (MART) is a treatment for asthma where a single combined inhaler is used for both maintenance and reliever purposes, instead of having separate preventer (brown) and reliever (blue) inhalers. 

Inhalation is the main route for administration of drugs for conditions such as asthma or chronic obstructive pulmonary disease. The advantage of administering drugs by inhaler is that drugs are delivered directly to the site of action within the airways.

Knowing how to use Very Brief Advice to instigate a quit attempt and supporting smokers who are ready to quit is the business of every healthcare professional.Treating tobacco dependency systematically and effectively will have a significant impact on the triple aim:

Concerns about the environmental impact of the propellant gases used in pressurised metered dose inhalers (pMDIs) and the plastics used in all single-use inhaler devices have made them an important focus for efforts to reduce the environmental impact of the NHS.

This position statement outlines the rationale, core principles and practical steps for implementing risk-stratified asthma care across UK primary care, ensuring patients at medium and high risk receive timely review, optimisation of therapy and personalised support to reduce future risk.

A Single Patient Record, which is available to patients and healthcare professionals from different care settings alike, and includes information on investigations, care records, results, medical notes by clinicians and coding information, would optimise resources and improve patient care and out